|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Net premiums earned | |||||
| Investment income | |||||
| Net realized gains (losses) on securities: | |||||
| Net realized gains (losses) on security sales | |||||
| Net holding period gains (losses) on securities | |||||
| Net impairment losses recognized in earnings | |||||
| Net impairment losses | |||||
| Total net realized gains (losses) on securities | |||||
| Fees and other revenues | |||||
| Service revenues | |||||
| Total revenues | |||||
| Expenses | |||||
| Losses and loss adjustment expenses | |||||
| Policy acquisition costs | |||||
| Other underwriting expenses | |||||
| Policyholder credit expense | |||||
| Investment expenses | |||||
| Service expenses | |||||
| Interest expense | |||||
| Goodwill impairment | |||||
| Total expenses | |||||
| Net Income | |||||
| Income before income taxes | |||||
| Provision for income taxes | |||||
| Net income | |||||
| Less: Preferred share dividends and other | |||||
| Net income available to common shareholders | |||||
| Average common shares outstanding – Basic | |||||
| Net effect of dilutive stock-based compensation | |||||
| Total average equivalent common shares – Diluted | |||||
| Basic: Earnings per common share (usd per share) | |||||
| Diluted: Earnings per common share (usd per share) | |||||
| Other Comprehensive Income (Loss) | |||||
| Changes in: | |||||
| Total net unrealized gains (losses) on fixed-maturity securities | |||||
| Net unrealized losses on forecasted transactions | |||||
| Foreign currency translation adjustment | |||||
| Other comprehensive income (loss) | |||||
| Comprehensive income (loss) | |||||
Loading...